NASDAQ:SLNO Soleno Therapeutics (SLNO) Stock Price, News & Analysis $48.48 +1.53 (+3.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$47.56▼$49.2850-Day Range$38.94▼$51.5552-Week Range$3.69▼$53.82Volume205,369 shsAverage Volume400,252 shsMarket Capitalization$1.62 billionP/E RatioN/ADividend YieldN/APrice Target$60.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Soleno Therapeutics alerts: Email Address Soleno Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.14 Rating ScoreUpside/Downside24.4% Upside$60.33 Price TargetShort InterestBearish18.74% of Float Sold ShortDividend StrengthN/ASustainability-0.55Upright™ Environmental ScoreNews Sentiment0.75Based on 5 Articles This WeekInsider TradingSelling Shares$37.04 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.36) to ($2.42) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.69 out of 5 starsMedical Sector172nd out of 936 stocksElectromedical Equipment Industry4th out of 22 stocks 2.6 Analyst's Opinion Consensus RatingSoleno Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSoleno Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Soleno Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.74% of the float of Soleno Therapeutics has been sold short.Short Interest Ratio / Days to CoverSoleno Therapeutics has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in Soleno Therapeutics has recently increased by 13.68%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSoleno Therapeutics does not currently pay a dividend.Dividend GrowthSoleno Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSoleno Therapeutics has received a 73.45% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for genetic diseases" and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Soleno Therapeutics is -0.55. Previous Next 3.8 News and Social Media Coverage News SentimentSoleno Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Soleno Therapeutics this week, compared to 2 articles on an average week.Search Interest2 people have searched for SLNO on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Soleno Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Soleno Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,038,709.00 in company stock.Percentage Held by Insiders12.30% of the stock of Soleno Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.42% of the stock of Soleno Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Soleno Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Soleno Therapeutics are expected to decrease in the coming year, from ($2.36) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Soleno Therapeutics is -18.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Soleno Therapeutics is -18.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSoleno Therapeutics has a P/B Ratio of 9.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Soleno Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Soleno Therapeutics Stock (NASDAQ:SLNO)Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.Read More SLNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLNO Stock News HeadlinesJuly 4, 2024 | insidertrades.comInsider Selling: Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Sells 2,170 Shares of StockJuly 24 at 11:43 AM | bizjournals.comPeninsula biotech lines up employees for stock bonuses triggered by FDA decisionsJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 24 at 3:51 AM | americanbankingnews.comSoleno Therapeutics, Inc. (NASDAQ:SLNO) Given Consensus Recommendation of "Buy" by BrokeragesJuly 19, 2024 | nz.finance.yahoo.comSoleno Therapeutics, Inc. (SLNO)June 28, 2024 | globenewswire.comSoleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi SyndromeJune 24, 2024 | globenewswire.comSoleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 6, 2024 | 247wallst.com3 Stocks That Have Seen Higher Share Gains Than Super Micro ComputerJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 22, 2024 | globenewswire.comSoleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024May 22, 2024 | globenewswire.comSoleno Therapeutics to Participate in Upcoming Investor ConferencesMay 15, 2024 | globenewswire.comSoleno Therapeutics Stands with the Prader-Willi Syndrome CommunityMay 13, 2024 | markets.businessinsider.comSoleno Therapeutics (SLNO) Receives a Buy from Stifel NicolausMay 11, 2024 | msn.comBaird Initiates Coverage of Soleno Therapeutics (SLNO) with Outperform RecommendationMay 10, 2024 | investorplace.comSLNO Stock Earnings: Soleno Therapeutics Misses EPS for Q1 2024May 9, 2024 | markets.businessinsider.comSoleno Therapeutics’ DCCR Poised for FDA Approval and Blockbuster Sales: An Analyst’s Bullish OutlookMay 9, 2024 | globenewswire.comSoleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | finance.yahoo.comWhile institutions invested in Soleno Therapeutics, Inc. (NASDAQ:SLNO) benefited from last week's 4.8% gain, private equity firms stood to gain the mostSee More Headlines Receive SLNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryN/A Current SymbolNASDAQ:SLNO CUSIPN/A CIK1484565 Webwww.soleno.life Phone(650) 213-8444Fax650-213-8383Employees33Year FoundedN/APrice Target and Rating Average Stock Price Target$60.33 High Stock Price Target$93.00 Low Stock Price Target$35.00 Potential Upside/Downside+23.4%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,990,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-61.84% Return on Assets-46.87% Debt Debt-to-Equity RatioN/A Current Ratio11.23 Quick Ratio11.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.16 per share Price / Book9.47Miscellaneous Outstanding Shares33,410,000Free Float29,301,000Market Cap$1.63 billion OptionableOptionable Beta-1.40 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Anish Bhatnagar M.D. (Age 54)President, CEO, COO & Director Comp: $1.06MMr. James H. MacKaness (Age 60)Chief Financial Officer Comp: $640kMs. Patricia C. Hirano M.P.H. (Age 58)Senior Vice President of Regulatory Affairs Comp: $493kMs. Lauren BudesheimVice President of PeopleMs. Kristen Yen M.S. (Age 55)Senior Vice President of Clinical Operations Comp: $317.19kDr. Neil M. Cowen M.B.A.Ph.D., Senior Vice President of Drug DevelopmentMs. Meredith Manning M.B.A. (Age 52)Chief Commercial Officer Dr. Michael Huang M.D. (Age 50)Senior Vice President of Clinical Development More ExecutivesKey CompetitorsLarimar TherapeuticsNASDAQ:LRMRRhythm PharmaceuticalsNASDAQ:RYTMRockwell MedicalNASDAQ:RMTIMasimoNASDAQ:MASITransMedics GroupNASDAQ:TMDXView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 29,745 shares on 7/26/2024Ownership: 0.400%Bank of New York Mellon CorpBought 88,799 shares on 7/26/2024Ownership: 0.266%Assenagon Asset Management S.A.Bought 729,841 shares on 7/18/2024Ownership: 2.184%SG Americas Securities LLCBought 13,941 shares on 7/12/2024Ownership: 0.042%Bhatnagar AnishSold 19,256 sharesTotal: $799,894.24 ($41.54/share)View All Insider TransactionsView All Institutional Transactions SLNO Stock Analysis - Frequently Asked Questions How have SLNO shares performed this year? Soleno Therapeutics' stock was trading at $40.25 at the beginning of 2024. Since then, SLNO shares have increased by 20.4% and is now trading at $48.48. View the best growth stocks for 2024 here. How were Soleno Therapeutics' earnings last quarter? Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its quarterly earnings data on Thursday, May, 9th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.29. When did Soleno Therapeutics' stock split? Soleno Therapeutics shares reverse split on Friday, August 26th 2022. The 1-15 reverse split was announced on Friday, August 26th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 26th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Soleno Therapeutics' major shareholders? Top institutional investors of Soleno Therapeutics include Assenagon Asset Management S.A. (2.18%), Allspring Global Investments Holdings LLC (0.40%), Bank of New York Mellon Corp (0.27%) and SG Americas Securities LLC (0.04%). Insiders that own company stock include Vivo Opportunity, Llc, Perceptive Advisors Llc, Jack W Schuler, Bhatnagar Anish, James H Mackaness and Kristen Yen. View institutional ownership trends. How do I buy shares of Soleno Therapeutics? Shares of SLNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Soleno Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB) and Miragen Therapeutics (MGEN). This page (NASDAQ:SLNO) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soleno Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soleno Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
